{"nctId":"NCT00783718","briefTitle":"Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis","startDateStruct":{"date":"2009-01"},"conditions":["Ulcerative Colitis"],"count":895,"armGroups":[{"label":"Vedolizumab","type":"EXPERIMENTAL","interventionNames":["Drug: vedolizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"vedolizumab","otherNames":["Entyvio","MLN0002","MLN02","LDP-02"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nEach patient must meet all of the following inclusion criteria to be enrolled in the study:\n\n1. Diagnosis of moderately to severely active ulcerative colitis\n2. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance at least 1 of the following agents:\n\n   1. Immunomodulators\n   2. Tumor necrosis factor-alpha (TNFα) antagonists\n   3. Corticosteroids\n3. May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol\n\nExclusion Criteria:\n\n1. Evidence of abdominal abscess at the initial screening visit\n2. Extensive colonic resection, subtotal or total colectomy\n3. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine\n4. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol\n5. Chronic hepatitis B or C infection\n6. Active or latent tuberculosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Induction Phase: Percentage of Participants With a Clinical Response at Week 6","description":"Clinical response is defined as a reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point.\n\nThe Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"47.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Phase: Percentage of Participants in Clinical Remission at Week 52","description":"Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \\> 1 point.\n\nThe Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null},{"groupId":"OG001","value":"41.8","spread":null},{"groupId":"OG002","value":"44.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Percentage of Participants in Clinical Remission at Week 6","description":"Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \\> 1 point.\n\nThe Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"16.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Induction Phase: Percentage of Participants With Mucosal Healing at Week 6","description":"Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point.\n\nThe Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows:\n\n0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"40.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Durable Clinical Response","description":"Durable clinical response is defined as reduction in complete Mayo score of ≥ 3 points and ≥ 30% from Baseline (Week 0) with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or absolute rectal bleeding subscore of ≤ 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving durable clinical response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"56.6","spread":null},{"groupId":"OG002","value":"52.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Mucosal Healing at Week 52","description":"Mucosal healing is defined as a Mayo endoscopic subscore of ≤ 1 point.\n\nThe Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Endoscopic findings were scored on a scale from 0 to 3 as follows:\n\n0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern, mild friability); 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving mucosal healing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"51.6","spread":null},{"groupId":"OG002","value":"56.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Durable Clinical Remission","description":"Durable clinical remission is defined as complete Mayo score of ≤ 2 points and no individual subscore \\> 1 point at both Weeks 6 and 52. The Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving durable clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":null},{"groupId":"OG001","value":"20.5","spread":null},{"groupId":"OG002","value":"24.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Maintenance Phase: Percentage of Participants With Corticosteroid-free Remission at Week 52","description":"Clinical Remission is defined as a complete Mayo score of ≤ 2 points and no individual subscore \\> 1 point. Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission at Week 52.\n\nThe Mayo Score is a standard assessment tool to measure ulcerative colitis disease activity in clinical trials. The index consists of 4 components: two that are patient reported (rectal bleeding and stool frequency), a global assessment by the physician, and an endoscopic subscore. Each component is scored on a scale from 0 to 3 and the complete score ranges from 1 to 12 (higher scores indicate greater disease activity).\n\nAll participants who prematurely discontinued for any reason were considered as not achieving corticosteroid-free remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.9","spread":null},{"groupId":"OG001","value":"31.4","spread":null},{"groupId":"OG002","value":"45.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":149},"commonTop":["Headache","Nasopharyngitis","Colitis ulcerative","Arthralgia","Upper respiratory tract infection"]}}}